Access to public health and medical information published in or related to Africa
African Index Medicus Database
From this page you can:
| Return to the search interface |
Search results
11 result(s) search for keyword(s) 'Hepacivirus' 
Add the result to your basket Refine your search Generate the RSS feed of the searchDendritic Cells in Hepatitis C Virus Infection / Rafik Mona Mohamed
Title : Dendritic Cells in Hepatitis C Virus Infection Authors: Rafik Mona Mohamed, Author ; Zakaria Nahla Mohamed, Author ; Mohamed Hala Ghareeb, Author ; Nesrine Aly Mohamed, Author Publisher: Cairo [Egypt] : Pan Arab league of continuous medical education Publication Date: 2017 Series: The Egyptian Journal of Hospital Medicine, ISSN 2090-7125 No. 66 Pagination: p.123-126 Layout: Journal Article Languages : French Keywords: Dendritic Cells Hepacivirus Hepatitis C, Chronic Abstract: Background: The global prevalence of chronic hepatitis C is estimated at 2.8%. There is markedly higher prevalence in the Middle East about 14.7% in Egypt. Dendritic cells (DCs) are one of the major Antigen presenting cells in the body. They bridge innate and adaptive immunity and impact priming of HCVspecific immune responses. The current study was aimed to investigate the DC activation status, and their role in interaction with natural killer (NK) cells utilizing different setups with healthy NK and HCV+ DC, HCV+ NK and healthy DC, healthy DC and healthy NK and finally HCV+ NK and HCV+ DC in the presence of HCV peptides and a ratio of 5 NK: 1DC. Results: DC-NK interaction in chronic HCV infection is mainly affected by the affection of DCs by HCV leading to a maturation defect (decreased expression of HLA DR, CD 86 and CD 83). Healthy NK cells were able to stimulate the maturation of DCs particularly with core peptide whereas NS3-4 had no effect. When DCs were healthy, all peptides were able to produce significant maturation of DCs even when cocultured with HCV+ NK cells. Co-cultured HCV+ NK cells and HCV+ DCs showed significantly higher apoptosis of both cells. This could be attributed to the immature moDCs more with chronic HCV infection due to the fact that immature DCs typically under express HLA-class I molecules that would protect from NK-mediated lysis. Conclusion: Cross-talk between DCs and NK cells plays an important role in the induction of both the innate and adaptive immune systems. HCV infection was found to impair the maturation of DCs. Thus consequently affecting its antigen presentation and T cell allostimulatory capacity and rendering them more liable to NK mediated lysis which could explain the persistence of infection and chronicity Dendritic Cells in Hepatitis C Virus Infection [] / Rafik Mona Mohamed, Author ; Zakaria Nahla Mohamed, Author ; Mohamed Hala Ghareeb, Author ; Nesrine Aly Mohamed, Author . - Cairo (Egypt) : Pan Arab league of continuous medical education, 2017 . - p.123-126 : Journal Article. - (The Egyptian Journal of Hospital Medicine, ISSN 2090-7125; 66) .
Languages : French
Keywords: Dendritic Cells Hepacivirus Hepatitis C, Chronic Abstract: Background: The global prevalence of chronic hepatitis C is estimated at 2.8%. There is markedly higher prevalence in the Middle East about 14.7% in Egypt. Dendritic cells (DCs) are one of the major Antigen presenting cells in the body. They bridge innate and adaptive immunity and impact priming of HCVspecific immune responses. The current study was aimed to investigate the DC activation status, and their role in interaction with natural killer (NK) cells utilizing different setups with healthy NK and HCV+ DC, HCV+ NK and healthy DC, healthy DC and healthy NK and finally HCV+ NK and HCV+ DC in the presence of HCV peptides and a ratio of 5 NK: 1DC. Results: DC-NK interaction in chronic HCV infection is mainly affected by the affection of DCs by HCV leading to a maturation defect (decreased expression of HLA DR, CD 86 and CD 83). Healthy NK cells were able to stimulate the maturation of DCs particularly with core peptide whereas NS3-4 had no effect. When DCs were healthy, all peptides were able to produce significant maturation of DCs even when cocultured with HCV+ NK cells. Co-cultured HCV+ NK cells and HCV+ DCs showed significantly higher apoptosis of both cells. This could be attributed to the immature moDCs more with chronic HCV infection due to the fact that immature DCs typically under express HLA-class I molecules that would protect from NK-mediated lysis. Conclusion: Cross-talk between DCs and NK cells plays an important role in the induction of both the innate and adaptive immune systems. HCV infection was found to impair the maturation of DCs. Thus consequently affecting its antigen presentation and T cell allostimulatory capacity and rendering them more liable to NK mediated lysis which could explain the persistence of infection and chronicity Copies
Barcode Call number Media type Location Section Status No copy 
Title : Evaluation of Ledipasvir plus Sofosbuvir for treatment of compensated and decompensated HCV cirrhotic patients Publisher: Cairo [Egypt] : Pan Arab league of continuous medical education Publication Date: 2017 Series: The Egyptian Journal of Hospital Medicine, ISSN 2090-7125 No. 66 Pagination: p.46-51, fig., tab. Layout: Journal Article ISSN (or other code): 2090-7125 Languages : French Keywords: Hepatitis B virus Hepacivirus HIV Infections Antiviral Agents ledipasvir sofosbuvir drug combination [Supplementary Concept] Egypt Abstract: Background:unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct acting antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The first generation of DAAs includes boceprevir and telaprevir, which are protease inhibitors and were approved for clinical use in 2011. The cure rate for genotype 1 patients increased from 45% to 70% when boceprevir or telaprevir was added to standard PEG-IFN/ribavirin. More effective and less toxic second generation DAAs supplanted these drugs by 2013. The second generation of DAAs includes sofosbuvir, simeprevir and fixed combination medicines containing ledipasvir plus sofosbuvir and Viekira Pak. These drugs increase cure rates to over 90% without the need for interferon and effectively treat all HCV genotypes. With these drugs the "cure HCV" goal has become a reality. The aim of this study was to assess of ledipasvir plus sofosbuvir as treatment of HCV infection in patients with advanced liver disease including cirrhotic patients with child B and C. Patients and methods:in this prospective study, seventy five HCV PCR positive patients were classified into three groups according to child score. Each group included twenty five patients. All patients received ledipasvir plus sofosbuvir for six months. For all patients thorough medical history, clinical examination, kidney function tests, liver function tests, complete blood count, pelvi-abdominal ultrasound, HCVantibodies, hepatitis C viral RNA, quantitative, HbsAg, alpha fetoprotein as baseline screening. HCV PCR done for all patients at end of treatment and three months later to detect sustained virological response (SVR12). Patients with combined HCV and HBV infection, hepatic or extrahepatic malignancies and late child C were excluded. Results: showed that no statistical significant difference were detected in patients of group A as regard liver function tests before and after treatment and SVR12 achieved by 96%. Patients of group B showed significant statistical difference as regard liver function tests before and after treatment with SVR12 achieved by 88%. In patients of group C there were significant statistical difference in liver function tests with SVR12 achieved by 80%. Also there were clinical improvement in patients of group B and C after end of treatment. Conclusion:it could be concluded that there will be a dramatic improvement in HCV therapy followed the introduction of oral medicines that directly inhibiting the replication cycle of HCV. The combination pill contains a fixed-dose of ledipasvir 90 mg and sofosbuvir 400 mg, two direct-acting antiviral agents against HCV. Ledipasvir is an inhibitor of the NS5A protein, which is required for HCV replication. Sofosbuvir inhibits the HCV NS5B RNA-dependent RNA polymerase, which is also required for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form a pharmacologically active triphosphate that can incorporate into the HCV RNA. Ledipasvir plus sofosbuvir can be used safely in treatment of compensated and decompensated post hepatitis C liver cirrhosis. SVR12 can be achieved by 96% in patients with early cirrhosis (child A), 88% in patients with child B cirrhosis and 80% in patients with child C with subsequent improvement in liver functions Link for e-copy: http://egyptianjournal.net78.net/ Evaluation of Ledipasvir plus Sofosbuvir for treatment of compensated and decompensated HCV cirrhotic patients [] . - Cairo (Egypt) : Pan Arab league of continuous medical education, 2017 . - p.46-51, fig., tab. : Journal Article. - (The Egyptian Journal of Hospital Medicine, ISSN 2090-7125; 66) .
ISSN : 2090-7125
Languages : French
Keywords: Hepatitis B virus Hepacivirus HIV Infections Antiviral Agents ledipasvir sofosbuvir drug combination [Supplementary Concept] Egypt Abstract: Background:unlike human immunodeficiency virus (HIV) and hepatitis B virus (HBV), hepatitis C virus (HCV) infection is a curable disease. Current direct acting antiviral agent (DAA) targets are focused on HCV NS3/4A protein (protease), NS5B protein (polymerase) and NS5A protein. The first generation of DAAs includes boceprevir and telaprevir, which are protease inhibitors and were approved for clinical use in 2011. The cure rate for genotype 1 patients increased from 45% to 70% when boceprevir or telaprevir was added to standard PEG-IFN/ribavirin. More effective and less toxic second generation DAAs supplanted these drugs by 2013. The second generation of DAAs includes sofosbuvir, simeprevir and fixed combination medicines containing ledipasvir plus sofosbuvir and Viekira Pak. These drugs increase cure rates to over 90% without the need for interferon and effectively treat all HCV genotypes. With these drugs the "cure HCV" goal has become a reality. The aim of this study was to assess of ledipasvir plus sofosbuvir as treatment of HCV infection in patients with advanced liver disease including cirrhotic patients with child B and C. Patients and methods:in this prospective study, seventy five HCV PCR positive patients were classified into three groups according to child score. Each group included twenty five patients. All patients received ledipasvir plus sofosbuvir for six months. For all patients thorough medical history, clinical examination, kidney function tests, liver function tests, complete blood count, pelvi-abdominal ultrasound, HCVantibodies, hepatitis C viral RNA, quantitative, HbsAg, alpha fetoprotein as baseline screening. HCV PCR done for all patients at end of treatment and three months later to detect sustained virological response (SVR12). Patients with combined HCV and HBV infection, hepatic or extrahepatic malignancies and late child C were excluded. Results: showed that no statistical significant difference were detected in patients of group A as regard liver function tests before and after treatment and SVR12 achieved by 96%. Patients of group B showed significant statistical difference as regard liver function tests before and after treatment with SVR12 achieved by 88%. In patients of group C there were significant statistical difference in liver function tests with SVR12 achieved by 80%. Also there were clinical improvement in patients of group B and C after end of treatment. Conclusion:it could be concluded that there will be a dramatic improvement in HCV therapy followed the introduction of oral medicines that directly inhibiting the replication cycle of HCV. The combination pill contains a fixed-dose of ledipasvir 90 mg and sofosbuvir 400 mg, two direct-acting antiviral agents against HCV. Ledipasvir is an inhibitor of the NS5A protein, which is required for HCV replication. Sofosbuvir inhibits the HCV NS5B RNA-dependent RNA polymerase, which is also required for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form a pharmacologically active triphosphate that can incorporate into the HCV RNA. Ledipasvir plus sofosbuvir can be used safely in treatment of compensated and decompensated post hepatitis C liver cirrhosis. SVR12 can be achieved by 96% in patients with early cirrhosis (child A), 88% in patients with child B cirrhosis and 80% in patients with child C with subsequent improvement in liver functions Link for e-copy: http://egyptianjournal.net78.net/ Copies
Barcode Call number Media type Location Section Status No copy 
Title : Frequency of cholelithiasis in patients with chronic liver disease: A hospital-based study Authors: Mona Ahmed Abdelmaksoud ; Mostafa H. El-Shamy, Author ; Hala I. M. Hussein, Author ; Bihery S. Ahmed, Author ; Hussein Ahmed, Author ; Hoda Abdel-Aziz El-Hady, Author Publication Date: 2016 Pagination: p.134-141, tab. Layout: Journal Article ISSN (or other code): 2090-7184 Languages : English Keywords: Cholelithiasis- epidemiology Liver Cirrhosis Liver Diseases Risk Factors Hepacivirus Egypt Abstract: Background and study aim: Liver Cirrhosis is a strong and a common known risk factor for Cholelithiasis. Cholelithiasis is a multifactorial disease, based on a complex interaction of environmental and genetic factors. The primary aim of this study is to determine the frequency of cholelithiasis in chronic liver disease (CLD) patients admitted to Zagazig university hospitals. The secondary aim is to determine the risk factors and their association with the underlying etiology and severity of liver disease.Patients and Methods: We conducted a hospital based study including 131 patients with chronic liver disease based on clinical, laboratory and Ultrasonographic findings. Demographic, clinical and etiological data were recorded, using a pre-coded questionnaire. A number of laboratory tests as fasting plasma glucose, total cholesterol, triglyceride, aspartate aminotransferase (AST), alanine amino-transferase (ALT), alkaline phosphatase (ALP), hepatitis B surface antigen (HBsAg), and antibody to hepatitis C virus (HCV-Ab) were analyzed.Results: The number of registered cases was 131 with age (52.9±11.7).There were 55 (42%) males and 76 (58%) females. Hepatitis C (HCV) was present in 101 (77%) cases. The prevalence of cholelithiasis was 50.4%% (66 of 131 patients). Most of cholelithiasis patients presented with child C stage (68.2%), followed by child B (21.2%) and the least one was Child A. Hepatitis C (10.6%) was found to be associated with cholelithiasis (75.8%), followed by hepatitis B (13.6%). Auto-immune disease, diabetes mellitus, contraceptive pills and obesity are considered risk factors for cholelithiasis. Conclusion: Cholelithiasis tends to occur more frequently in patients with decompensated CLD. The higher incidence of cholelithiasis in CLD appears to be associated with HCV infection. This is an important parameter to be considered in a country with high prevalence of HCV as Egypt. Frequency of cholelithiasis in patients with chronic liver disease: A hospital-based study [] / Mona Ahmed Abdelmaksoud ; Mostafa H. El-Shamy, Author ; Hala I. M. Hussein, Author ; Bihery S. Ahmed, Author ; Hussein Ahmed, Author ; Hoda Abdel-Aziz El-Hady, Author . - 2016 . - p.134-141, tab. : Journal Article.
ISSN : 2090-7184
Languages : English
Keywords: Cholelithiasis- epidemiology Liver Cirrhosis Liver Diseases Risk Factors Hepacivirus Egypt Abstract: Background and study aim: Liver Cirrhosis is a strong and a common known risk factor for Cholelithiasis. Cholelithiasis is a multifactorial disease, based on a complex interaction of environmental and genetic factors. The primary aim of this study is to determine the frequency of cholelithiasis in chronic liver disease (CLD) patients admitted to Zagazig university hospitals. The secondary aim is to determine the risk factors and their association with the underlying etiology and severity of liver disease.Patients and Methods: We conducted a hospital based study including 131 patients with chronic liver disease based on clinical, laboratory and Ultrasonographic findings. Demographic, clinical and etiological data were recorded, using a pre-coded questionnaire. A number of laboratory tests as fasting plasma glucose, total cholesterol, triglyceride, aspartate aminotransferase (AST), alanine amino-transferase (ALT), alkaline phosphatase (ALP), hepatitis B surface antigen (HBsAg), and antibody to hepatitis C virus (HCV-Ab) were analyzed.Results: The number of registered cases was 131 with age (52.9±11.7).There were 55 (42%) males and 76 (58%) females. Hepatitis C (HCV) was present in 101 (77%) cases. The prevalence of cholelithiasis was 50.4%% (66 of 131 patients). Most of cholelithiasis patients presented with child C stage (68.2%), followed by child B (21.2%) and the least one was Child A. Hepatitis C (10.6%) was found to be associated with cholelithiasis (75.8%), followed by hepatitis B (13.6%). Auto-immune disease, diabetes mellitus, contraceptive pills and obesity are considered risk factors for cholelithiasis. Conclusion: Cholelithiasis tends to occur more frequently in patients with decompensated CLD. The higher incidence of cholelithiasis in CLD appears to be associated with HCV infection. This is an important parameter to be considered in a country with high prevalence of HCV as Egypt. E-copies: Download the digital copy of the document
Frequency of cholelithiasis in patients with chronic liver diseaseAdobe Acrobat PDF
Title : Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria Authors: Moses P. Adoga ; Edmund B. Banwat, Author ; Joseph C. Forbi, Author ; Lohya Nimzing, Author ; Christopher R. Pam, Author ; Silas D. Gyar, Author ; Yusuf A. Agabi, Author ; Simon M. Agwale, Author Publisher: Sassari [Italy] : University of Sassari - Department of Biomedical Sciences Publication Date: 2009 Series: Journal of Infection in Developing Countries, ISSN 1972-2680 No. 3(7) Pagination: p.539-547, fig., tab. Layout: Journal Article ISSN (or other code): 1972-2680 Languages : English Keywords: HIV Hepatitis B virus Hepacivirus Seroepidemiologic Studies Risk factors Nigeria - Nasarawa State Abstract: Background: Published data on HIV; HBV; and HCV in correctional facilities in Nigeria is scarce. We set out to establish the seroprevalence; co-infection; and risk factors for these infections for the first time among prison inmates in Nasarawa State; Nigeria. Methodology: In a cross-sectional study conducted between April and May; 2007; blood samples were collected from 300 male prisoners of a mean age of 29.2 years; in the state's four medium-security prisons (overall population: 587). Prior to the study; ethical clearance and informed consent were obtained and structured questionnaires were administered. Samples were analyzed for HIV; HBsAg; and HCV using anti-HIV 1 +2-EIA- avicenna; ShantestTM-HBsAg ELISA; and anti-HCV-EIA-avicenna; respectively. Specimens initially reactive for HIV were retested with vironostika microelisa. Data were analyzed using SPSS version 13.0. P values = 0.05 were considered significant. Results: Of the 300 subjects; 54 (18.0); 69 (23.0); and 37 (12.3) tested positive for HIV; HBV; and HCV; respectively. Co-infections were eight (2.7) for HIV/HBV and two (0.7) for HBV/HCV. Those aged 21-26 years were more likely to be infected with HIV and HBV; while those aged 33-38 years had the highest HCV infection. Associated risk factors included duration in prison; previous incarceration (for HIV; HBV and HCV); intra-prison anal sex; multiple sex partners (for HIV and HBV); ignorance of transmission modes; blood transfusion; and alcohol consumption (for HBV and HCV). No inmate injected drugs. Conclusions: The overall outcome represents the need for prison-focused intervention initiatives in Nigeria. Injected drug use is an unlikely major transmission mode among Nigerian inmates Human immunonodeficiency virus, hepatitis B virus and hepatitis C virus: sero-prevalence, co-infection and risk factors among prison inmates in Nasarawa State, Nigeria [] / Moses P. Adoga ; Edmund B. Banwat, Author ; Joseph C. Forbi, Author ; Lohya Nimzing, Author ; Christopher R. Pam, Author ; Silas D. Gyar, Author ; Yusuf A. Agabi, Author ; Simon M. Agwale, Author . - Sassari (Viale San Pietro, 37, 07100, Italy) : University of Sassari - Department of Biomedical Sciences, 2009 . - p.539-547, fig., tab. : Journal Article. - (Journal of Infection in Developing Countries, ISSN 1972-2680; 3(7)) .
ISSN : 1972-2680
Languages : English
Keywords: HIV Hepatitis B virus Hepacivirus Seroepidemiologic Studies Risk factors Nigeria - Nasarawa State Abstract: Background: Published data on HIV; HBV; and HCV in correctional facilities in Nigeria is scarce. We set out to establish the seroprevalence; co-infection; and risk factors for these infections for the first time among prison inmates in Nasarawa State; Nigeria. Methodology: In a cross-sectional study conducted between April and May; 2007; blood samples were collected from 300 male prisoners of a mean age of 29.2 years; in the state's four medium-security prisons (overall population: 587). Prior to the study; ethical clearance and informed consent were obtained and structured questionnaires were administered. Samples were analyzed for HIV; HBsAg; and HCV using anti-HIV 1 +2-EIA- avicenna; ShantestTM-HBsAg ELISA; and anti-HCV-EIA-avicenna; respectively. Specimens initially reactive for HIV were retested with vironostika microelisa. Data were analyzed using SPSS version 13.0. P values = 0.05 were considered significant. Results: Of the 300 subjects; 54 (18.0); 69 (23.0); and 37 (12.3) tested positive for HIV; HBV; and HCV; respectively. Co-infections were eight (2.7) for HIV/HBV and two (0.7) for HBV/HCV. Those aged 21-26 years were more likely to be infected with HIV and HBV; while those aged 33-38 years had the highest HCV infection. Associated risk factors included duration in prison; previous incarceration (for HIV; HBV and HCV); intra-prison anal sex; multiple sex partners (for HIV and HBV); ignorance of transmission modes; blood transfusion; and alcohol consumption (for HBV and HCV). No inmate injected drugs. Conclusions: The overall outcome represents the need for prison-focused intervention initiatives in Nigeria. Injected drug use is an unlikely major transmission mode among Nigerian inmates E-copies: Download the digital copy of the document
Human immunonodeficiency virus, hepatitis B virus and hepatitis CAdobe Acrobat PDF
Title : Mean Platelet Volume as a Fibrosis Marker in Patients with Chronic Hepatitis C Authors: Gamal Saad EL- Deeb ; Rawhia Hassan EL- Edel, Author ; Somaia Abd El-Mohsen Shehab El-Deen, Author ; Mohamed Sobhy Laban, Author Publisher: Zagazig [Egypt] : Endemic and Tropical Medicine Department, Faculty of Medicine, Zagazig University Publication Date: 2014 Series: Afro-Egyptian Journal of Infectious and Endemic Diseases, ISSN 2090-7184 No. 4(4) Pagination: p.172-183, fig., tab. Layout: Journal Article ISSN (or other code): 2090-7184 Languages : English Keywords: Hepatitis C, Chronic Hepacivirus Fibrosis Mean Platelet Volume Patients Egypt Abstract: Background and study aim: Liver biopsy limitations push us to search for new non invasive methods to detect liver fibrosis such as serum markers. The aim of this study is to evaluate mean platelet volume (MPV) as a fibrosis marker in patient with chronic hepatitis C. Patients and methods: 150 patients diagnosed with chronic hepatitis C infection refereed to Tanta Fever Hospital in period from May 2013 to January 2014 and 20 healthy volunteers as a control were included. All of them were tested for Mean Platelet Volume (MPV) in comparison with who done liver biopsy as standard. Results: Statistically significant differences in MPV and Platelet Count were seen in patients with chronic hepatitis C (CHC) compared to healthy controls (MPV: 8.95 ± 1.39fL vs. 7.57 ± 0.68 fl, P-value = 0.043; PC 226.03 ±68.36 vs. 188.9±46.49, P-value = 0.02) Multi-variate Logistic regression analysis shows only 5 variables remained as independent risk factors for fibrosis progression: (MPV, Schistosomiasis, ALT, AST and Prothrombin time). AST (OR 1.11, 95% CI 1.02 to 1.21), ALT (OR 0.92, 95% CI 0.86 to 0.99), PT (OR 2.11, 95% CI 1.15 to 3.88), and MPV (OR 2.28, 95% CI 1.22 to 4.25). Cut-off values were calculated for diagnostic performance, and the cut-off value for MPV was 9.22 fl., sensitivity 75.5%, specificity 62%, PPV 40.3%, NPPV 93.4% and Accuracy rate 61.8%. Conclusion: We suggest that high MPV levels (especially those over 9.22 fl) may help to predict advanced fibrosis in patients with CHC. However, it should not be forgotten that MPV is not a specific marker for fibrosis, and the negative predictive rate seems more valuable to exclude a high fibrosis ratio in patients with CHC Mean Platelet Volume as a Fibrosis Marker in Patients with Chronic Hepatitis C [] / Gamal Saad EL- Deeb ; Rawhia Hassan EL- Edel, Author ; Somaia Abd El-Mohsen Shehab El-Deen, Author ; Mohamed Sobhy Laban, Author . - Zagazig (44519, Egypt) : Endemic and Tropical Medicine Department, Faculty of Medicine, Zagazig University, 2014 . - p.172-183, fig., tab. : Journal Article. - (Afro-Egyptian Journal of Infectious and Endemic Diseases, ISSN 2090-7184; 4(4)) .
ISSN : 2090-7184
Languages : English
Keywords: Hepatitis C, Chronic Hepacivirus Fibrosis Mean Platelet Volume Patients Egypt Abstract: Background and study aim: Liver biopsy limitations push us to search for new non invasive methods to detect liver fibrosis such as serum markers. The aim of this study is to evaluate mean platelet volume (MPV) as a fibrosis marker in patient with chronic hepatitis C. Patients and methods: 150 patients diagnosed with chronic hepatitis C infection refereed to Tanta Fever Hospital in period from May 2013 to January 2014 and 20 healthy volunteers as a control were included. All of them were tested for Mean Platelet Volume (MPV) in comparison with who done liver biopsy as standard. Results: Statistically significant differences in MPV and Platelet Count were seen in patients with chronic hepatitis C (CHC) compared to healthy controls (MPV: 8.95 ± 1.39fL vs. 7.57 ± 0.68 fl, P-value = 0.043; PC 226.03 ±68.36 vs. 188.9±46.49, P-value = 0.02) Multi-variate Logistic regression analysis shows only 5 variables remained as independent risk factors for fibrosis progression: (MPV, Schistosomiasis, ALT, AST and Prothrombin time). AST (OR 1.11, 95% CI 1.02 to 1.21), ALT (OR 0.92, 95% CI 0.86 to 0.99), PT (OR 2.11, 95% CI 1.15 to 3.88), and MPV (OR 2.28, 95% CI 1.22 to 4.25). Cut-off values were calculated for diagnostic performance, and the cut-off value for MPV was 9.22 fl., sensitivity 75.5%, specificity 62%, PPV 40.3%, NPPV 93.4% and Accuracy rate 61.8%. Conclusion: We suggest that high MPV levels (especially those over 9.22 fl) may help to predict advanced fibrosis in patients with CHC. However, it should not be forgotten that MPV is not a specific marker for fibrosis, and the negative predictive rate seems more valuable to exclude a high fibrosis ratio in patients with CHC E-copies: Download the digital copy of the document
Mean Platelet Volume as a Fibrosis Marker in Patients with Chronic Hepatitis CAdobe Acrobat PDF
Permalink
Permalink
Permalink
Permalink
Permalink
Permalink
